January 31, 2024 02:50 PM EST

Ruling in SCOTUS mifepristone case could lead to endless litigation, industry says

Lia DeGroot

Industry groups, members of Congress and state legislatures are among the wave of parties that asked the Supreme Court on Tuesday to preserve the FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ruling in SCOTUS mifepristone case could lead to endless litigation, industry says

Lia DeGroot

Sign up to read this article for free.

Rocket shares promising long-term results from rare heart disease gene therapy in small study

FDA offers more guidance on developing cell and gene therapies

A rare neurological disease is Sage’s last, best hope after failures in depression

Neurogene patient had life-threatening side effect in Rett syndrome study

Novartis strikes radiopharma deal with Ratio worth up to $745M

Are programs with compounded GLP-1s safe for your population?

Rul­ing in SCO­TUS mifepri­s­tone case could lead to end­less lit­i­ga­tion, in­dus­try says

Lia DeGroot

Sign up to read this article for free.

Rock­et shares promis­ing long-term re­sults from rare heart dis­ease gene ther­a­py in small study

FDA of­fers more guid­ance on de­vel­op­ing cell and gene ther­a­pies

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

Neu­ro­gene pa­tient had life-threat­en­ing side ef­fect in Rett syn­drome study

No­var­tis strikes ra­dio­phar­ma deal with Ra­tio worth up to $745M

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Ruling in SCOTUS mifepristone case could lead to endless litigation, industry says

Rocket shares promising long-term results from rare heart disease gene therapy in small study

FDA offers more guidance on developing cell and gene therapies

A rare neurological disease is Sage’s last, best hope after failures in depression

Neurogene patient had life-threatening side effect in Rett syndrome study

Novartis strikes radiopharma deal with Ratio worth up to $745M

Are programs with compounded GLP-1s safe for your population?